<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002280</url>
  </required_header>
  <id_info>
    <org_study_id>039C</org_study_id>
    <secondary_id>AI454-904</secondary_id>
    <nct_id>NCT00002280</nct_id>
  </id_info>
  <brief_title>A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine</brief_title>
  <official_title>An Open Label Study Regimen of Videx (2',3'-Dideoxyinosine, ddI) in Children With Acquired Immunodeficiency Syndrome (AIDS) Who Have Demonstrated Significant Deterioration or Intolerance to Zidovudine (Retrovir)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to make didanosine (ddI) available to children with AIDS who are&#xD;
      clinically deteriorating on zidovudine (AZT) or intolerant to AZT and cannot enter the Phase&#xD;
      II ddI programs due to protocol exclusion or geographic location.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">November 1994</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Concomitant medications for the treatment of complications of AIDS.&#xD;
&#xD;
          -  CAUTION:&#xD;
&#xD;
          -  Concomitant use of ddI with the following drugs must be done with extreme caution:&#xD;
&#xD;
          -  Other nucleosides (e.g., ganciclovir).&#xD;
&#xD;
          -  Drugs with toxicities similar to those observed with ddI (e.g., phenytoin).&#xD;
&#xD;
          -  Drugs with significant pancreatic toxicities, including many drugs used for treatment&#xD;
             of major opportunistic infections.&#xD;
&#xD;
          -  Use of Sulfonamides or intravenous pentamidine for treatment of acute Pneumocystis&#xD;
             carinii pneumonia (PCP) requires discontinuation of ddI for a week following treatment&#xD;
             of PCP.&#xD;
&#xD;
          -  Caution should also be exercised with patients having intractable diarrhea or patients&#xD;
             following a low sodium diet.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
        - Diagnosis of AIDS. Demonstrated either significant deterioration despite parenteral&#xD;
        dosing with zidovudine (AZT) or significant intolerance to AZT.&#xD;
&#xD;
        Signed informed consent by parent or legal guardian. Evaluations every 7-14 days while&#xD;
        taking ddI for the first 4 months. Monthly follow-up is required thereafter.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Acute pancreatitis or any history of pancreatitis.&#xD;
&#xD;
          -  Seizures or a history of seizure disorder.&#xD;
&#xD;
          -  Grade I or greater peripheral neuropathy.&#xD;
&#xD;
          -  Preexisting cardiomyopathy.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Chemotherapy with cytotoxic agents.&#xD;
&#xD;
          -  AVOID:&#xD;
&#xD;
          -  Those agents that may cause pancreatitis such as:&#xD;
&#xD;
          -  Pentamidine.&#xD;
&#xD;
          -  Sulfonamides.&#xD;
&#xD;
          -  Antituberculosis drugs.&#xD;
&#xD;
          -  Cimetidine.&#xD;
&#xD;
          -  Ranitidine.&#xD;
&#xD;
          -  Corticosteroids.&#xD;
&#xD;
          -  NOTE the cautionary statement in Patient Inclusion Concurrent Medication.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Acute pancreatitis or any history of pancreatitis.&#xD;
&#xD;
          -  Seizures or a history of seizure disorder.&#xD;
&#xD;
          -  Grade I or greater peripheral neuropathy.&#xD;
&#xD;
          -  Preexisting cardiomyopathy.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 15 days of study entry:&#xD;
&#xD;
          -  Any anti-retroviral except zidovudine (AZT).&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bristol - Myers Squibb Co</name>
      <address>
        <city>Wallingford</city>
        <state>Connecticut</state>
        <zip>064927600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>August 4, 2011</last_update_submitted>
  <last_update_submitted_qc>August 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <keyword>Didanosine</keyword>
  <keyword>Drugs, Investigational</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Didanosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

